CliffBio
small molecule

RIVFLOZA

NEDOSIRAN SODIUM

Loss of exclusivityOctober 2038latest FDA-listed patent expiry
CompanyNOVO NORDISK INC

Drug detail

Brand nameRIVFLOZA
Active ingredientNEDOSIRAN SODIUM
StrengthEQ 80MG BASE/0.5ML (EQ 160MG BASE/ML)
Dosage formSOLUTION
RouteINJECTION
ModalitySmall molecule
FDA approvalSeptember 2023
Marketing statusRX

Listed patents

PatentExpiresType
11661604October 2038substance, product
11286488October 2038substance, product
11053502October 2035substance, product
11359203October 2035substance, product
10738311October 2035substance, product
10351854October 2035substance, product

Regulatory exclusivity

CodeExpires
ODE-531March 2032
ODE-443September 2030
NCESeptember 2028
NPPMarch 2028

More from NOVO NORDISK INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

RIVFLOZA patent cliff — loss of exclusivity October 2038 | CliffBio